Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients

What is already known about this subject Before this study, few data were available on the potential effect of genetic variants of P-glycoprotein or the CYP3A5 enzyme on the pharmacokinetic variability of protease inhibitors (PI). MDR1 C3435T polymorphism was often linked with the pharmacokinetic va...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Solas, Caroline, Simon, Nicolas, Drogoul, Marie-Pierre, Quaranta, Sylvie, Frixon-Marin, Véronique, Bourgarel-Rey, Véronique, Brunet, Corinne, Gastaut, Jean-Albert, Durand, Alain, Lacarelle, Bruno, Poizot-Martin, Isabelle
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2007
Assuntos:
Pharmacogenetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000655/
https://ncbi.nlm.nih.gov/pubmed/17517050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02903.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados